Propanc Biopharma, Inc. is a development stage healthcare company focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer. Together with our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Our leading products are variations upon our novel formulation and involve or employ proenzymes, which are inactive precursors of enzymes.View Company PDF
We are developing a therapeutic solution for the treatment of patients with advanced stages of cancer targeting solid tumors. Our therapy has anti-cancer effects that block tumor growth and its aggressive dissemination.View Our Product Pipeline
Instead of targeting tumor cell death, we focus on inducing cell differentiation. We convince malignant cells to stop proliferating and encourage them to continue their work as a specific cell type.What Makes Us Different
Our strong partnerships are helping to advance and perfect our technology and candidates.
The Andalusian Public Foundation for biomedical research in eastern Andalusia, Alejandro Otero-FIBAO is a non-profit foundation specializing in the comprehensive management of biomedical research.
We have a Joint IP Ownership and Commercialization Agreement with Bath University.
Our ongoing joint research collaboration with the University of Grenada and Universidad de Jaen involved investigating the effects of PRP on cancer cells, identifying molecular target identification and new compound screenings.
With the help of vivoPharm, we are conducting animal testing on PRP to determine its safety and efficacy, as well as determining metabolic effects prior to conducting human studies.
We have partnered with Adaptive Biotechnologies to characterize immune responses in animals and later in patients, post treatment with PRP.
Our ongoing joint research collaboration with The ibs.GRANADA involves studying the in-vivo effect of the anti-tumoral formulation of PRP against cancer stem cells.
We are building an IP portfolio around our scientific understanding of the effects of proenzymes in cancer, identifying new formulations, new routes of administration and potential new therapeutic targets.